BHC:CA:TSX-Bausch Health Companies Inc (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 36.94

Change

+1.04 (+2.90)%

Market Cap

CAD 12.77B

Volume

0.43M

Average Target Price

CAD 43.00 (+16.40%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
WEED:CA Canopy Growth Corporation

+1.72 (+5.34%)

CAD12.32B N/A N/A
APHA:CA Aphria Inc

+0.83 (+5.02%)

CAD5.23B 57.08 598.01
CRON:CA Cronos Group Inc

+0.40 (+4.12%)

CAD3.76B 46.76 N/A
ACB:CA Aurora Cannabis Inc

+0.59 (+6.13%)

CAD1.90B 1,171.00 N/A
OGI:CA OrganiGram Holdings Inc

+0.24 (+8.16%)

CAD0.88B -99,999.99 N/A
HEXO:CA HEXO Corp

+0.56 (+8.52%)

CAD0.80B N/A N/A
CWEB:CA Charlotte's Web Holdings, Inc

+0.07 (+1.43%)

CAD0.71B 120.37 N/A
GUD:CA Knight Therapeutics Inc

+0.05 (+0.96%)

CAD0.67B 16.27 4.71
HLS:CA HLS Therapeutics Inc

-0.16 (-0.83%)

CAD0.60B N/A 30.75
TH:CA Theratechnologies Inc

-0.02 (-0.44%)

CAD0.43B 954.70 80.88

ETFs Containing BHC:CA

Symbol Name Weight Mer Price(Change) Market Cap
CJNK SPDR ICE BofAML Broad Hig.. 0.00 % 0.15 %

N/A

CAD0.07B
FXM:CA CI First Asset Morningsta.. 0.00 % 0.60 %

+0.14 (+0.75%)

CAD0.23B
QXM:CA CI First Asset Morningsta.. 0.00 % 0.50 %

N/A

CAD0.08B
XFC:CA iShares MSCI Multifactor .. 0.00 % 0.45 %

+0.18 (+0.68%)

CAD0.05B
QHY:CA Mackenzie US High Yield B.. 0.00 % 0.40 %

N/A

CAD0.11B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.87% 61% D- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.87% 61% D- 91% A-
Trailing 12 Months  
Capital Gain 59.22% 77% C+ 72% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.22% 77% C+ 70% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -2.28% 50% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.28% 50% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 24.87% 88% B+ 35% F
Risk Adjusted Return -9.15% 50% F 18% F
Market Capitalization 12.77B 100% A+ 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 19.95 13% F 4% F
Price / Cash Flow Ratio 11.49 10% F 27% F
EV/EBITDA 17.58 53% F 35% F
Management Effectiveness  
Return on Equity -64.22% 39% F 9% F
Return on Invested Capital 6.57% 93% A 70% C-
Return on Assets 2.56% 90% A- 63% D
Debt to Equity Ratio 4,471.96% 5% F 1% F
Technical Ratios  
Short Ratio 3.35 30% F 25% F
Short Percent 0.78% 75% C 90% A-
Beta 1.73 46% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector